Derya BERK, Tülay ŞAHİN, Murat TEKİN, Mine SOLAK, Kamil TOKER

Pediatrik bir olguda yarık damak operasyonu sırasındaki malign hipertermi şüphesi

Malign hipertermi (MH) genel anestezi esnasında volatil ajanların veya depolarizan kas gevşeticilerin kullanımı ile tetiklenen, iskelet kaslarının hipermetabolik myopatisi olup nadir fakat hayatı tehdit edici bir durumdur. Daha önceki genel anestezi deneyimi sırasında malign hipertermiye ait bir hikayesi olmayan 14 aylık bir çocukta, yarık damak nedeniyle sevoşuran kullanılarak gerçekleştirilen genel anestezi esnasındaki MH şüphesi uyandıran klinik parametreleri sunmayı amaçladık. Malign hipertermide başarılı tedavi; erken hızlı tanı, tetikleyici ajan maruziyetinin hızla sonlandırılması, yeterli dozlarda dantrolenin iv dozunun verilmesi ve semptomatik tedavinin başlatılmasına dayalıdır.

Suspected malignant hyperthermia in a pediatric patient during the cleft palate surgery

Malignant hyperthermia (MH) is a rare, but life-threatining condition which is the hypermetabolic myopathy of skeleatal muscles triggered by the use of volatile agents or depolarizing muscle relaxants during general anesthesia. We aimed at presenting the clinical parameters which evoke suspicion of MH during general anesthesia by using sevofluran in a 14-month-old patient who had a cleft palate surgery, and who did not have any history of MH experience before. Success of the treatment of malignant hyperthermia is based on early and fast diagnosis, immediate cessation of triggering agents, intravenous administration of dantrolene in a sufficient dosage and beginning an adequate symptomatic treatment.

PDF

___

1.Gronert GA, Antognini JF, Pessah IN: Malignant Hyperthermia in: Miller RD Anesthesia 5th edition. NewYork Churchill Livingstone; 2000; 1033-1019.
2.Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare. 2007; 24; 2-21.
3.Hopkins P.M. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth 2011;107: 48-56.
4.Migita T, Mukaida K, Kawamoto M, Kobayashi M, Nishino I, Yuget O. Propofol-induced changes in myoplasmic calcium concentrations in cultured human skeletal muscles from RYR1 mutation carriers. Anaesth Intensive Care. 2007 Dec; 35: 894-898.
5.Claxton BA, Cross MH, Hopkins PM. No response to trigger agents in a malignant hyperthermia-susceptible patient. Br J Anaesth 2002; 88: 870-873.
6.Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997; 41: 955-966.
7.Larach MG, Locallia AR, Allen GC, et al: A clinical grading scala to predict malignant hyperthermia suspeptibility. Anesthesiology 1994; Apr; 80: 771-779.